OneMedNet (ONMD)
Market Price (2/27/2026): $0.69 | Market Cap: $36.3 MilSector: Health Care | Industry: Health Care Technology
OneMedNet (ONMD)
Market Price (2/27/2026): $0.69Market Cap: $36.3 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Artificial Intelligence. Themes include Health Data Analytics, AI in Healthcare Management, Show more. | Weak multi-year price returns2Y Excs Rtn is -45%, 3Y Excs Rtn is -166% | Penny stockMkt Price is 0.7 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -9.2 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1866% | ||
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -48% | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 147% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1579%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1588% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -9.8% | ||
| High stock price volatilityVol 12M is 243% | ||
| Key risksONMD key risks include [1] severe financial instability and a going concern warning, Show more. |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Artificial Intelligence. Themes include Health Data Analytics, AI in Healthcare Management, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -45%, 3Y Excs Rtn is -166% |
| Penny stockMkt Price is 0.7 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -9.2 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1866% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -48% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 147% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1579%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1588% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -9.8% |
| High stock price volatilityVol 12M is 243% |
| Key risksONMD key risks include [1] severe financial instability and a going concern warning, Show more. |
Qualitative Assessment
AI Analysis | Feedback
OneMedNet (ONMD) stock has lost about 65% since 10/31/2025 because of the following key factors:
1. Significant Share Dilution from Public Offerings. OneMedNet filed a Prospectus Supplement (Form S-1) registering a primary offering of up to 11,500,000 shares of common stock and a secondary offering of up to 28,152,560 shares for resale. Considering approximately 51 million shares outstanding as of November 7, 2025, this represents a substantial potential dilution that could significantly depress the stock price.
2. Persistent Weak Financial Performance and Liquidity Issues. The company reported consistently negative profitability ratios, including an EBIT margin of -393.3% and a gross margin of -144% in late November 2025. Furthermore, OneMedNet's Q3 2025 earnings, reported on November 14, 2025, showed total revenue of $177K with $0 in subscription revenue, an operating loss of $2.24M, and a net loss of $741K for the quarter. The company's current ratio of approximately 0.29 indicated that its short-term obligations significantly exceeded its liquid assets, raising concerns about its ability to meet immediate financial commitments and indicating a "going concern risk."
Show more
1. Significant Share Dilution from Public Offerings. OneMedNet filed a Prospectus Supplement (Form S-1) registering a primary offering of up to 11,500,000 shares of common stock and a secondary offering of up to 28,152,560 shares for resale. Considering approximately 51 million shares outstanding as of November 7, 2025, this represents a substantial potential dilution that could significantly depress the stock price.
2. Persistent Weak Financial Performance and Liquidity Issues. The company reported consistently negative profitability ratios, including an EBIT margin of -393.3% and a gross margin of -144% in late November 2025. Furthermore, OneMedNet's Q3 2025 earnings, reported on November 14, 2025, showed total revenue of $177K with $0 in subscription revenue, an operating loss of $2.24M, and a net loss of $741K for the quarter. The company's current ratio of approximately 0.29 indicated that its short-term obligations significantly exceeded its liquid assets, raising concerns about its ability to meet immediate financial commitments and indicating a "going concern risk."
Show more
Stock Movement Drivers
Fundamental Drivers
The -66.7% change in ONMD stock from 10/31/2025 to 2/26/2026 was primarily driven by a -55.8% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2262026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.12 | 0.71 | -66.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 7.6% |
| P/S Multiple | 169.8 | 75.0 | -55.8% |
| Shares Outstanding (Mil) | 37 | 53 | -30.0% |
| Cumulative Contribution | -66.7% |
Market Drivers
10/31/2025 to 2/26/2026| Return | Correlation | |
|---|---|---|
| ONMD | -66.7% | |
| Market (SPY) | 1.1% | 11.9% |
| Sector (XLV) | 9.1% | -1.7% |
Fundamental Drivers
The 47.4% change in ONMD stock from 7/31/2025 to 2/26/2026 was primarily driven by a 144.4% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2262026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.48 | 0.71 | 47.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 0 | -7.0% |
| P/S Multiple | 30.7 | 75.0 | 144.4% |
| Shares Outstanding (Mil) | 34 | 53 | -35.2% |
| Cumulative Contribution | 47.4% |
Market Drivers
7/31/2025 to 2/26/2026| Return | Correlation | |
|---|---|---|
| ONMD | 47.4% | |
| Market (SPY) | 9.4% | 3.6% |
| Sector (XLV) | 21.2% | -7.5% |
Fundamental Drivers
The -31.5% change in ONMD stock from 1/31/2025 to 2/26/2026 was primarily driven by a -48.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312025 | 2262026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.03 | 0.71 | -31.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 0 | -48.3% |
| P/S Multiple | 31.5 | 75.0 | 138.1% |
| Shares Outstanding (Mil) | 29 | 53 | -44.4% |
| Cumulative Contribution | -31.5% |
Market Drivers
1/31/2025 to 2/26/2026| Return | Correlation | |
|---|---|---|
| ONMD | -31.5% | |
| Market (SPY) | 15.5% | 6.0% |
| Sector (XLV) | 8.6% | -2.7% |
Fundamental Drivers
nullnull
Market Drivers
1/31/2023 to 2/26/2026| Return | Correlation | |
|---|---|---|
| ONMD | -93.3% | |
| Market (SPY) | 75.9% | 3.5% |
| Sector (XLV) | 23.5% | -3.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ONMD Return | 2% | 3% | -92% | 68% | -19% | -41% | -93% |
| Peers Return | -2% | -48% | 4% | -26% | -19% | -30% | -78% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 85% |
Monthly Win Rates [3] | |||||||
| ONMD Win Rate | 86% | 83% | 67% | 50% | 42% | 0% | |
| Peers Win Rate | 47% | 35% | 48% | 40% | 42% | 10% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| ONMD Max Drawdown | -0% | -0% | -93% | -47% | -76% | -47% | |
| Peers Max Drawdown | -20% | -58% | -25% | -36% | -34% | -32% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: IQV, VEEV, HCAT, DH, CERT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/26/2026 (YTD)
How Low Can It Go
| Event | ONMD | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -93.2% | -25.4% |
| % Gain to Breakeven | 1370.5% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to IQV, VEEV, HCAT, DH, CERT
In The Past
OneMedNet's stock fell -93.2% during the 2022 Inflation Shock from a high on 10/9/2023. A -93.2% loss requires a 1370.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About OneMedNet (ONMD)
Data Knights Acquisition Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on businesses in the data centers and internet technology sectors. The company was incorporated in 2021 and is based in Chessington, the United Kingdom.
AI Analysis | Feedback
Here are 1-3 brief analogies for OneMedNet (ONMD):
- Shutterstock for medical images used by researchers and pharma
- ZoomInfo for medical imaging data, but for scientific research and development
AI Analysis | Feedback
- ipartment® Platform: A cloud-based platform for the secure, compliant exchange and monetization of de-identified medical imaging data.
- Real-World Evidence (RWE) Data Services: Provides access to de-identified medical imaging data sets to support research, drug development, and AI algorithm training.
- Healthcare Data Monetization Solutions: Enables healthcare providers to generate revenue from their de-identified medical imaging data assets.
AI Analysis | Feedback
OneMedNet (ONMD) primarily sells its services to other companies and organizations, not individuals.
Based on their public statements and SEC filings, OneMedNet operates a Real World Data (RWD) network connecting data contributors (hospitals, imaging centers) with "data requestors" (their customers). While OneMedNet does not publicly disclose specific customer names that account for a significant portion of its revenue (e.g., 10% or more), they clearly define the categories of organizations that utilize their services. Therefore, their major customers fall into the following categories:
- Life Science Companies: This broad category encompasses various companies involved in research, development, and manufacturing of biological products and medical therapies.
- Pharmaceutical and Biotech Companies: These companies utilize OneMedNet's de-identified medical imaging data for drug discovery, clinical trials, post-market surveillance, and therapeutic development.
- Medical Device Companies: Manufacturers of medical devices leverage the data for product development, validation, and performance monitoring.
- Academic Institutions and Research Organizations: Universities and research bodies use the data for scientific studies, hypothesis generation, and clinical research.
- Artificial Intelligence (AI) Developers: Companies and researchers focused on developing AI algorithms for medical imaging and diagnostics are key customers, using the data for training, validation, and benchmarking their models.
As no specific public customer companies are named in OneMedNet's financial disclosures, we cannot list individual company names or their symbols.
AI Analysis | Feedback
Aaron Green, President and Chief Executive Officer
Aaron Green assumed the role of President and Chief Executive Officer of OneMedNet in April 2024, having previously served as President since May 2023. He brings over two decades of experience in healthcare IT to his position. Green has a strong track record of driving growth and business transformations. His prior roles include Vice President Cloud Solutions at Optum Insights, which was acquired by United Health Group, and General Manager Radiology Imaging at Change Healthcare (NASDAQ:CHNG). He also spent 15 years at McKesson (NYSE:MCK), where he advanced to Division Vice President, Sales.
Bob Golden, Chief Financial Officer and Corporate Secretary
Bob Golden was appointed Chief Financial Officer of OneMedNet in September 2024, and also serves as Corporate Secretary and a Director. He is a Certified Public Accountant with more than 40 years of experience in financial management. Golden's expertise encompasses financial strategy, business development, and mergers and acquisitions. His past experience includes serving as Managing Partner at Cohen, Bender & Golden LLP since 2015, and holding CFO positions at Promo Shop, Inc. and iKahan Media, Inc. He has also been a member of the Board of Directors for Talon International, Inc.
Jeffrey Yu, MD, Vice President and Chief Medical Officer
Dr. Jeffrey Yu is the Founder, Vice President, Chief Medical Officer, and Chairman of the Board for OneMedNet, which he founded in 2009. He is a board-certified Radiologist with 28 years of extensive healthcare IT experience. Dr. Yu's early research and development led to the creation of the BEAM solution, designed to facilitate secure and efficient sharing of patient imaging studies.
AI Analysis | Feedback
The key risks to OneMedNet (ONMD) business operations are primarily centered around its financial viability, customer concentration, and intense market competition.
- Financial Instability and Going Concern Risk: OneMedNet faces significant financial challenges, including ongoing net losses, a negative equity position, and severe liquidity constraints, with only approximately $0.1 million in cash as of June 2025. The company's reliance on external financing, often through equity dilution, and a "going concern" flag underscore its precarious financial state. Its revenues are described as minuscule and sub-scale in comparison to its operating losses.
- Customer Concentration and Revenue Volatility: A substantial portion of OneMedNet's revenue has historically been concentrated with a few key customers. In 2023 and 2022, Change Healthcare and Siemens Medical Solutions USA collectively accounted for 53% and 52% of the company's revenues, respectively. The potential loss of one or more of these significant customers could lead to a material adverse effect on its revenue and overall business. Additionally, the company experienced a drastic 92.35% decrease in total operating revenue from December 31, 2023, to December 31, 2024, signaling significant challenges in revenue generation and overall financial health.
- Competitive Pressures and Market Traction: OneMedNet operates in a highly competitive real-world data (RWD) market. The company faces competitive pressures from larger RWD platforms and has struggled to gain significant market traction. While OneMedNet is pursuing new partnerships and showcasing its platforms, its product growth stems from a very small base, leading to questions about its competitive advantages and potential for meaningful market penetration.
AI Analysis | Feedback
The emergence and increasing sophistication of synthetic data generation technologies represent a clear threat. These technologies aim to create artificial datasets that mimic the statistical properties and patterns of real-world patient data, but without containing any actual patient information. If synthetic data can achieve sufficient fidelity and reliability for various research and AI training applications, it could significantly reduce the demand for access to real-world de-identified data networks, such as OneMedNet's iRWD™, thereby disrupting its core business model by offering an alternative solution that inherently sidesteps many privacy and access complexities.
AI Analysis | Feedback
OneMedNet (ONMD) participates in several addressable markets related to healthcare data solutions, primarily focusing on Real-World Data (RWD), de-identified health data, healthcare data monetization, and healthcare data annotation.
- The global Real-World Data (RWD) market was estimated at approximately $1.64 billion in 2024 and is projected to reach around $6.37 billion by 2034, with a Compound Annual Growth Rate (CAGR) of 14.54% from 2025 to 2034. In North America, the RWD market size exceeded $710 million in 2024 and is expected to grow at a CAGR of 14.58% during the forecast period.
- The global de-identified health data market was valued at $7.80 billion in 2024 and is anticipated to reach $15.85 billion by 2032, with a CAGR of 9.32% from 2025 to 2032. The U.S. de-identified health data market size was $1.94 billion in 2024 and is projected to grow to $3.97 billion by 2032. North America held the largest share of this market in 2024, exceeding 31.53%.
- The global healthcare data monetization solutions market was valued at $998.3 million in 2024 and is estimated to grow at an 18.2% CAGR from 2025 to 2034, reaching $5.27 billion in 2034. The U.S. segment of this market was valued at $309.47 million in 2024 and is projected to reach approximately $1.39 billion by 2034. North America dominated the global market in 2024, holding a 42% market share.
- The global healthcare data annotation market was valued at $1.5 billion in 2025 and is projected to reach $2.8 billion by 2030.
- OneMedNet also notes that the broader AI-enabled healthcare opportunity is estimated at $868 billion by 2030.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for OneMedNet (ONMD)
OneMedNet (ONMD) is positioned for future revenue growth over the next 2-3 years, driven by several strategic initiatives and expansions.- Expansion of the iRWD™ Platform and Provider Network: OneMedNet is actively transitioning from its legacy BEAM platform to enhance its iRWD™ sales, with a complete discontinuation of BEAM planned by 2025. The company has significantly expanded its provider network to 1,750 sites, gaining access to 136 million clinical studies and over 5 billion administrative records and claims. This expansion of accessible real-world data is a core strategy to scale and decrease time to revenue by growing relationships with hospitals and academic medical centers.
- Diversification and Expansion into New Data Markets: OneMedNet's iRWD™ platform is crucial for innovation in various healthcare sectors, including drug development, medical device advancements, and AI applications across rare diseases, oncology, and cardiology. Beyond healthcare, the company leverages its proprietary AI for data anonymization in other industries such as finance, retail, and telecommunications. A recent strategic move includes expanding into the $1.5 billion healthcare data annotation market with its MedCase offering.
- Enhancement of AI-Powered Platform Capabilities: Continuous improvement of the iRWD™ platform, particularly through AI-driven de-identification, federated search, and multi-modal data integration, is a key driver. These technological advancements aim to accelerate platform development, thereby decreasing the time required for data search and curation. A partnership with Palantir to advance healthcare AI and data analytics further underscores this commitment to technological enhancement.
- Implementation of a New Subscription Revenue Model: OneMedNet has initiated a new subscription revenue model through a partnership with Circle CVI. This shift towards a subscription-based approach can provide more predictable and recurring revenue streams, fostering sustained financial growth.
AI Analysis | Feedback
Share Issuance
- OneMedNet completed $3.7 million in private placements of company securities in the second quarter of 2025, including $1.2 million from insiders. The proceeds are intended for working capital, general corporate purposes, and to accelerate sales execution and expand the iRWD™ platform.
- In June 2025, OneMedNet secured approximately $3.7 million through private placements of common stock at $0.42 per share. These proceeds are designated for working capital and general corporate purposes, and the company plans to continue its strategy of adding Bitcoin to its balance sheet.
- In September 2024, OneMedNet announced an additional $1.7 million funding through a follow-on private placement with an affiliate of Off the Chain Capital, where 1,918,591 shares of common stock were sold at $0.65 per share, along with warrants. This followed a previous private placement with Off the Chain Capital on July 24, 2024, which generated gross proceeds of $2.7 million. The net proceeds from these placements are for working capital and general corporate purposes, with plans to use a portion to purchase Bitcoin.
Inbound Investments
- Off the Chain Capital has strategically invested in OneMedNet, recognizing the business case of its platform and market position for long-term value creation.
- Yorkville Advisors Global committed to purchase up to $25.0 million of OneMedNet's common stock over a twenty-four-month period, subject to certain conditions, as part of a standby equity purchase agreement (SEPA) entered into on June 17, 2024.
- On June 18, 2024, Yorkville advanced $1.5 million to OneMedNet under a convertible promissory note due June 18, 2025, with the intention for it to be repaid through SEPA advances for working capital and general corporate purposes.
Capital Expenditures
- OneMedNet's capital expenditures for the quarter ending June 2025 were $3,000.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Is OneMedNet Stock Built to Withstand More Downside? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to ONMD.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 01302026 | ABT | Abbott Laboratories | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | 5.0% | 5.0% | -1.0% |
| 01302026 | VEEV | Veeva Systems | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -13.5% | -13.5% | -15.7% |
| 01162026 | BIIB | Biogen | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 16.0% | 16.0% | 0.0% |
| 01162026 | BMRN | BioMarin Pharmaceutical | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.5% | 12.5% | 0.0% |
| 01162026 | DOCS | Doximity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -40.9% | -40.9% | -42.4% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 4.28 |
| Mkt Cap | 0.6 |
| Rev LTM | 366 |
| Op Inc LTM | 8 |
| FCF LTM | 64 |
| FCF 3Y Avg | 53 |
| CFO LTM | 88 |
| CFO 3Y Avg | 69 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.3% |
| Rev Chg 3Y Avg | 5.6% |
| Rev Chg Q | 10.3% |
| QoQ Delta Rev Chg LTM | 2.5% |
| Op Mgn LTM | 0.4% |
| Op Mgn 3Y Avg | -2.7% |
| QoQ Delta Op Mgn LTM | -0.1% |
| CFO/Rev LTM | 20.4% |
| CFO/Rev 3Y Avg | 17.9% |
| FCF/Rev LTM | 13.7% |
| FCF/Rev 3Y Avg | 13.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.6 |
| P/S | 2.2 |
| P/EBIT | 6.0 |
| P/E | 10.3 |
| P/CFO | 5.9 |
| Total Yield | -2.2% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 3.5% |
| D/E | 0.4 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -25.7% |
| 3M Rtn | -33.2% |
| 6M Rtn | -35.1% |
| 12M Rtn | -36.2% |
| 3Y Rtn | -74.5% |
| 1M Excs Rtn | -24.7% |
| 3M Excs Rtn | -30.8% |
| 6M Excs Rtn | -43.7% |
| 12M Excs Rtn | -53.3% |
| 3Y Excs Rtn | -147.9% |
Price Behavior
Price Behavior
| Market Price | $0.71 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 06/24/2021 | |
| Distance from 52W High | -77.5% | |
| 50 Days | 200 Days | |
| DMA Price | $0.95 | $1.03 |
| DMA Trend | up | down |
| Distance from DMA | -26.1% | -31.3% |
| 3M | 1YR | |
| Volatility | 137.9% | 244.0% |
| Downside Capture | 453.47 | 277.75 |
| Upside Capture | -18.29 | 203.71 |
| Correlation (SPY) | -4.2% | 6.2% |
ONMD Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -1.72 | -0.63 | 3.30 | 1.62 | 0.86 | 0.58 |
| Up Beta | -6.69 | -9.93 | 2.46 | -6.61 | -1.10 | -0.69 |
| Down Beta | -2.66 | -2.31 | 0.94 | -1.16 | 0.44 | 0.27 |
| Up Capture | -341% | -146% | 100% | 925% | 515% | 40% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 10 | 18 | 24 | 55 | 106 | 275 |
| Down Capture | 424% | 513% | 481% | 293% | 163% | 112% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 9 | 22 | 36 | 68 | 141 | 363 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ONMD | |
|---|---|---|---|---|
| ONMD | -19.3% | 243.7% | 0.73 | - |
| Sector ETF (XLV) | 7.2% | 17.3% | 0.24 | -3.1% |
| Equity (SPY) | 17.1% | 19.4% | 0.69 | 5.8% |
| Gold (GLD) | 79.3% | 25.7% | 2.25 | 0.6% |
| Commodities (DBC) | 10.9% | 16.8% | 0.45 | -3.8% |
| Real Estate (VNQ) | 6.6% | 16.6% | 0.21 | -5.0% |
| Bitcoin (BTCUSD) | -23.4% | 45.1% | -0.46 | 4.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ONMD | |
|---|---|---|---|---|
| ONMD | -40.2% | 226.8% | 0.38 | - |
| Sector ETF (XLV) | 8.2% | 14.5% | 0.38 | -2.7% |
| Equity (SPY) | 13.6% | 17.0% | 0.63 | 2.9% |
| Gold (GLD) | 23.6% | 17.2% | 1.12 | -1.0% |
| Commodities (DBC) | 10.8% | 19.0% | 0.45 | -3.0% |
| Real Estate (VNQ) | 5.3% | 18.8% | 0.19 | -3.9% |
| Bitcoin (BTCUSD) | 4.0% | 57.0% | 0.29 | -0.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ONMD | |
|---|---|---|---|---|
| ONMD | -22.6% | 226.8% | 0.38 | - |
| Sector ETF (XLV) | 10.9% | 16.5% | 0.55 | -2.7% |
| Equity (SPY) | 15.5% | 17.9% | 0.74 | 2.9% |
| Gold (GLD) | 15.1% | 15.6% | 0.81 | -1.0% |
| Commodities (DBC) | 8.5% | 17.6% | 0.40 | -3.0% |
| Real Estate (VNQ) | 6.6% | 20.7% | 0.28 | -3.9% |
| Bitcoin (BTCUSD) | 66.3% | 66.8% | 1.06 | -0.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/23/2024 | 200.0% | 432.7% | 100.0% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 1 |
| # Negative | 0 | 0 | 0 |
| Median Positive | 200.0% | 432.7% | 100.0% |
| Median Negative | |||
| Max Positive | 200.0% | 432.7% | 100.0% |
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 04/15/2025 | 10-K |
| 09/30/2024 | 12/17/2024 | 10-Q |
| 06/30/2024 | 12/11/2024 | 10-Q |
| 03/31/2024 | 12/05/2024 | 10-Q |
| 12/31/2023 | 04/09/2024 | 10-K |
| 09/30/2023 | 11/20/2023 | 10-Q |
| 06/30/2023 | 10/02/2023 | 424B3 |
| 09/30/2022 | 12/18/2023 | 10-Q/A |
| 12/31/2021 | 07/22/2022 | S-4 |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Green, Aaron | Chief Executive Officer | Direct | Sell | 12232025 | 2.23 | 64,767 | 144,722 | 4,168,813 | Form |
| 2 | Green, Aaron | Chief Executive Officer | Direct | Sell | 12232025 | 1.20 | 61,555 | 73,903 | 2,166,006 | Form |
| 3 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.42 | 1,666,666 | 700,000 | 2,829,712 | Form |
| 4 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.77 | 16,500 | 12,705 | 5,200,511 | Form |
| 5 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.77 | 15,000 | 11,550 | 5,212,061 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.